Page 2 - Laurus Labs Ltd News

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Trading guide: Nifty eyes 23,200; BSE, Laurus Labs, Cipla on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy

Laurus Labs jumps 4% on huge volumes; Motilal projects 30% further upside

Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Laurus Labs soars 8% in 2 days, nears record high; analysts see more upside

The management expects better Q4 and a decent overall growth in FY27

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Stocks to buy: Graphite India, Laurus Labs, Tata Steel are on analyst radar

Stocks to buy today, February 26, 2026: Kunal Kamble of Bonanza Portfolio recommends buying Laurus Labs, Tata Steel, and Graphite India; here's why